market-trends is the sole category represented across all 1 tracked stories. MannKind is most often covered alongside Trulieve Cannabis, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 4.7 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about MannKind
market-trends is the sole category represented across all 1 tracked stories. MannKind is most often covered alongside Trulieve Cannabis, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 4.7 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.6. We currently track 1 Healthcare story that mention MannKind, all published on February 26, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering MannKind. Shared-story counts are live from our verified record — not editorial picks.
Trulieve Cannabis and MannKind reported mixed fourth-quarter results, with Trulieve beating earnings expectations despite a revenue miss. Meanwhile, MannKind delivered a significant revenue beat alongside an earnings shortfall, highlighting the divergent growth trajectories in the cannabis and biopharmaceutical sectors.